Financial Performance - Multi Ways Holdings Ltd reported net revenue of $26.44 million for the first half of 2025, representing an increase of 87.65% from $14.09 million in the same period last year [1] - The company's shares rose 59.6% to $0.40 in pre-market trading following the financial results announcement [1] Stock Movements - Indaptus Therapeutics Inc saw a surge of 62.1% to $3.21 after disclosing a significant investment by David E. Lazar [4] - X3 Holdings Co Ltd increased by 43.5% to $0.24 after previously dipping 90% [4] - Northann Corp rose 38.8% to $0.24 after engaging advisory services for business development [4] - Dynavax Technologies Corp gained 37.7% to $15.33 following Sanofi's agreement to acquire the company at $15.50 per share, valuing it at $2.2 billion [4] - Starfighters Space Inc shares jumped 18.2% to $15.30 amid post-IPO volatility [4] - Sidus Space Inc rose 17% to $1.93 after announcing a $25 million offering [4] - UiPath Inc increased by 8.7% to $17.35 after being announced as a member of the S&P Midcap 400 [4] Declines in Stock Prices - Picocela Inc fell 26.1% to $0.27 after a significant increase the previous day [4] - Can Fite Biopharma declined 25% to $0.18 following a reverse share split announcement [4] - Femasys Inc dropped 11.8% to $0.71 after filing a prospectus for a $9.8 million common stock offering [4] - SeaStar Medical Holding Corp fell 9.5% to $0.21 after announcing a reverse split [4] - EUDA Health Holdings Ltd dipped 8.3% to $1.75 after a previous jump of 41% [4]

Group 1 - UiPath Inc. will join the S&P Midcap 400, replacing Synovus Financial Corp., effective January 2, 2026, leading to a 6.8% increase in shares to $17.05 in after-hours trading [1] - Agios Pharmaceuticals Inc. received FDA approval for AQVESME™ for treating anemia in adults with alpha- or beta-thalassemia, but shares fell 1.4% to $24.59 [1] - Can Fite Biopharma announced a 1-for-3,000 reverse share split, resulting in a 28.8% drop in shares to $0.17 in after-hours trading [1] - Citius Pharmaceuticals reported a quarterly loss of 11 cents per share, better than the expected loss of 43 cents, causing shares to surge 22.1% to $1.27 [1] - Ramaco Resources announced a $100 million stock repurchase plan, leading to a 7.1% increase in shares to $18.09 in after-hours trading [1]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling over 300 points, down 0.79% to 46,222.90, NASDAQ down 0.76% to 22,531.74, and S&P 500 down 0.37% to 6,647.90 [1] - Consumer staples shares rose by 0.5%, while consumer discretionary stocks fell by 1.2% [1] Company Earnings - Home Depot reported third-quarter adjusted earnings of $3.74 per share, missing the analyst consensus estimate of $3.85 per share, but quarterly sales of $41.352 billion exceeded the consensus estimate of $41.137 billion [2] Commodity Market - Oil prices increased by 0.3% to $60.07, while gold decreased by 0.6% to $4,048.80. Silver fell by 1.14% to $50.025, and copper declined by 0.4% to $4.9935 [4] European Market - European shares were lower, with the eurozone's STOXX 600 down 1.5%, Spain's IBEX 35 down 1.8%, London's FTSE 100 down 1.3%, Germany's DAX 40 down 1.5%, and France's CAC 40 down 1.5% [5] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down 3.22%, Hong Kong's Hang Seng down 1.72%, China's Shanghai Composite down 0.81%, and India's BSE Sensex down 0.33% [6] Stock Movements - Olema Pharmaceuticals, Inc. shares surged 145% to $20.91 following positive Phase 3 results [8] - Can-Fite BioPharma Ltd. shares increased 66% to $0.5927 after reporting a significant patient survival milestone [8] - LifeMD, Inc. shares fell 27% to $3.4350 after reporting disappointing third-quarter results and lowering fourth-quarter sales guidance [8]

Core Insights - Can-Fite BioPharma Ltd. is advancing its oncology drug Namodenoson, which is being sought for compassionate use approval by leading U.S. medical centers for treating pancreatic carcinoma [1][2][4] - Namodenoson has received FDA approval for its first single-patient compassionate use treatment, indicating significant progress in its clinical development [2] - The company is conducting a Phase IIa study in Israel for advanced pancreatic adenocarcinoma patients, focusing on safety, clinical activity, and pharmacokinetics [3] Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company targeting multi-billion-dollar markets in cancer, liver, and inflammatory diseases [5] - The company’s lead drug candidate, Piclidenoson, has shown promising results in a Phase III trial for psoriasis and is expected to enter another pivotal Phase III trial [5] - Namodenoson is also being evaluated in multiple trials, including a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis [5] Drug Mechanism and Designation - Namodenoson is an orally bioavailable drug that selectively binds to the A3 adenosine receptor, which is highly expressed in diseased cells, contributing to its favorable safety profile [4] - The drug has received Orphan Drug Designation from the U.S. FDA, highlighting its potential as a therapeutic option for underserved patient populations [3][5]

Core Viewpoint - Can-Fite BioPharma Ltd. has announced a registered direct offering of 2,500,000 American Depositary Shares (ADSs) at a price of $1.20 per ADS, aiming to raise approximately $3.0 million for research, development, and general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about April 15, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering, before deducting fees and expenses, are anticipated to be $3.0 million [2]. Group 2: Company Overview - Can-Fite BioPharma is focused on developing small-molecule drugs for oncological and inflammatory diseases, targeting multi-billion dollar markets [5]. - The lead drug candidate, Piclidenoson, has recently reported topline results in a Phase III trial for psoriasis and is commencing another pivotal Phase III trial [5]. - Namodenoson, another key drug, is being evaluated in multiple trials for hepatocellular carcinoma (HCC) and has received Orphan Drug Designation and Fast Track Designation from the FDA [5]. - The company has a strong safety profile with over 1,600 patients involved in clinical studies to date [5].

Core Insights - Can-Fite BioPharma Ltd. reported financial results and clinical updates for the year ended December 31, 2024, highlighting advancements in its drug candidates and financial performance [1] Clinical & Development Milestones Achieved - Namodenoson has shown promising results in treating liver cancer, with a patient achieving complete cure and normal liver function [1] - The drug has protective effects beyond its anti-cancer activity, as presented at the 2025 ASCO Gastrointestinal Cancers Symposium [1] - Namodenoson received Orphan Drug Designation from the FDA for pancreatic cancer, allowing for potential market exclusivity for seven years post-approval [2] - A Phase IIa clinical trial for advanced pancreatic adenocarcinoma has been initiated [2] - Namodenoson was granted a patent for its use as an anti-obesity drug, with the patent expiring in 2042 [3][4] - Can-Fite initiated a pivotal Phase 3 study for Piclidenoson in treating psoriasis, with patient enrollment starting in Europe [5] - The company is developing Piclidenoson for Lowe Syndrome, with a Phase II study planned [6] - Can-Fite partnered with Vetbiolix to develop Piclidenoson for canine osteoarthritis, with potential peak sales of $445 million by 2034 [7][8] Financial Results - Revenues for 2024 were $0.67 million, a decrease of 9.3% from $0.74 million in 2023 [9] - Research and development expenses were $5.75 million, down 3.8% from $5.98 million in 2023, primarily due to reduced expenses related to Piclidenoson [10] - General and administrative expenses increased by 3.1% to $3.04 million, attributed to higher public relations costs [11] - Net loss for 2024 was $7.88 million, slightly higher than the $7.63 million loss in 2023 [12] - As of December 31, 2024, cash and cash equivalents totaled $7.88 million, down from $8.90 million in 2023 [13] Company Overview - Can-Fite BioPharma is focused on developing drugs for cancer, liver, and inflammatory diseases, with its lead candidates being Piclidenoson and Namodenoson [21]

Industry Overview - The psoriasis market is projected to reach $30 billion by 2030, with a significant shift towards oral drugs [1] Company Developments - Can-Fite BioPharma Ltd. has initiated a pivotal Phase 3 study for its oral drug Piclidenoson, targeting moderate to severe plaque psoriasis, with patient enrollment starting in Europe and expected to follow in the US and Canada [1][3] - The Phase 3 study is randomized, double-blind, and placebo-controlled, focusing on the safety and efficacy of Piclidenoson, with co-primary efficacy objectives including achieving a PASI score response of ≥75% and a sPGA score of 0 or 1 at Week 16 [2] - The FDA has requested two Phase 3 studies and encouraged the enrollment of adolescent patients due to the drug's strong safety profile [2] - Upon successful completion of the Phase 3 program, the company plans to submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Plan (MAA) to the EMA [3] Product Information - Piclidenoson is a first-in-class A3 adenosine receptor agonist, demonstrating an excellent safety profile and efficacy in previous clinical studies, targeting inflammatory cytokines IL-17 and IL-23 [4] - Can-Fite's lead drug candidate, Piclidenoson, is part of a broader pipeline that includes other drugs like Namodenoson, which is being evaluated for various cancers and has received Orphan Drug Designation and Fast Track Designation from the FDA [5]

Core Insights - Can-Fite BioPharma Ltd. has received FDA approval for compassionate use of its anti-cancer drug Namodenoson for a pancreatic cancer patient in the U.S. [1][3] - Namodenoson is currently undergoing multiple clinical trials, including a pivotal Phase III study for advanced liver cancer and a Phase IIa study for pancreatic cancer [3][5] - The drug has been granted Orphan Drug Designation by the FDA for pancreatic cancer, which may provide market exclusivity for seven years post-approval [4][6] Company Overview - Can-Fite BioPharma is a clinical-stage biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases [1][6] - The company’s lead drug candidate, Piclidenoson, has recently reported positive results in a Phase III trial for psoriasis [6] - Namodenoson has shown potential efficacy in treating various cancers, including colon, prostate, and melanoma, and has an excellent safety profile based on clinical studies involving over 1,600 patients [5][6]